R-pharm US — 1 certified H-1B filings (FY2017)
- 1
- Filings · FY2017
- $62k
- Median base · FY2017
- International Operations Specialist: Russia/Latin America
- Top role · 1 all-time
- NJ
- Top state · 1 all-time
R-pharm US filed 1 certified H-1B LCAs in FY2017, with a median base salary of $62k and the middle 50% of offers between $62k and $62k. Across all years it has 1 certified filings since FY2017, most often for International Operations Specialist: Russia/Latin America in New Jersey.
How much does R-pharm US pay H-1B workers?
Certified base salary by fiscal year: each box is the p25–p75 range, the heavy line the median, the whiskers reach p10–p90. $62k median in FY2017. Base pay only — hover a year for its figures.
How has R-pharm US's H-1B hiring changed by year?
1 certified filings on record (FY2017).
| Fiscal year | Filings | vs prior FY | Median base |
|---|---|---|---|
| FY2017 | 1 | — | $62k |
Which wage levels does R-pharm US file?
DOL prevailing-wage levels I–IV approximate experience tiers (I = entry, IV = fully competent). 0% of R-pharm US's filings sit at Level III–IV. A heavy I–II skew reads as entry-level or contractor-style hiring; a heavy IV skew as senior in-house roles — and higher levels earn more lottery entries.
Share of 1 filings with a wage level · all years
- Level II100.0%1
What jobs does R-pharm US sponsor for H-1B?
The most-filed job titles across all years (DOL titles, employer pay-grade codes stripped), with base-salary percentiles.
| Job title | Filings | Median base |
|---|---|---|
| International Operations Specialist: Russia/Latin America | 1 | $62k |
Where does R-pharm US hire H-1B workers?
Worksite states on the certified filings, all years. Deeper pink = more filings; hover a state for its figures.
| State | Filings | Median base |
|---|---|---|
| NJ | 1 | $62k |
What has R-pharm US filed recently?
Every certified LCA on record for R-pharm US: job title, worksite, prevailing-wage level and the offered base salary.
| FY | Job title | Base salary |
|---|---|---|
| 2017 | International Operations Specialist: Russia/Latin America | $62,109 |
Common questions about R-pharm US's H-1B filings
- How much does R-pharm US pay H-1B workers?
- R-pharm US's median certified H-1B base salary is $62k (FY2017), from 1 filings. See the full salary distribution and percentiles above.
- How many H-1B workers does R-pharm US sponsor?
- R-pharm US has 1 certified H-1B Labor Condition Applications on record (FY2017).
- What jobs does R-pharm US sponsor for H-1B?
- R-pharm US's most-sponsored H-1B roles include International Operations Specialist: Russia/Latin America.
- Where does R-pharm US hire H-1B workers?
- R-pharm US's top H-1B worksite states are NJ.
- Does a certified LCA mean an H-1B visa was approved?
- No. A Labor Condition Application (LCA) is the Department of Labor attestation an employer must have certified before filing an H-1B petition with USCIS. It records the job, worksite and offered wage, but not whether the petition was filed, selected in the lottery, or approved. Filing counts measure intent to sponsor, not headcount.
- What salary do these figures show?
- The base annual wage offered on the certified LCA, converted to a yearly amount. Bonus, equity, overtime and benefits are not included, so total compensation is typically higher. Figures are medians and percentiles over certified filings; wages above $5,000,000 a year are excluded as data-entry errors.
- What do prevailing-wage levels I–IV mean?
- The Department of Labor assigns each LCA an OES wage level from I (entry) to IV (fully competent) for the occupation and area. Under the FY2027 wage-weighted H-1B lottery rule, a higher level earns more selection entries, so an employer's level mix is a proxy for how senior its sponsored roles are.
Keep exploring
Calculate your H-1B lottery odds →orCheck out the insights →
Source: U.S. Department of Labor, Office of Foreign Labor Certification — certified LCA disclosure data through June 2026 (FY2017). An LCA is not an approved visa; pay figures are base salary and exclude bonus and equity. Methodology →